Uncertainty over Prolonged or Discontinued Drug Development Pipelines and Commercialization

The risk that development of drug candidates will be prolonged or discontinued, and that they will not reach commercialization, due to delays in clinical trials, insufficient efficacy, delays in data evaluation or obtaining regulatory approval, and other factors.